Finnish Researchers Investigate Medication Discontinuation Success in Chronic Myeloid Leukaemia Patients

Finnish Researchers Investigate Medication Discontinuation Success in Chronic Myeloid Leukaemia Patients

(IN BRIEF) Researchers in Finland have conducted a study to understand why some chronic myeloid leukaemia (CML) patients can safely discontinue their daily medication. CML is a type of blood cancer, and targeted drugs have significantly improved patient outcomes. However, the study aimed to develop treatments that allow patients to stop medication entirely, potentially achieving a cure. Successful medication discontinuation was found to be more common in patients with a favorable immune system. Patients with higher levels of natural killer cells (NK cells) and T cells capable of detecting cancer had a better chance of discontinuing treatment. The study results suggest that boosting the body’s immune response to cancer cells could be a key to allowing more CML patients to stop taking medication. Currently, around 40% of CML patients with an excellent treatment response can discontinue their medication. Researchers plan to further investigate drug discontinuation mechanisms and explore immune system activation in other cancer types. This study was funded by various organizations, including the European Research Council and the Cancer Foundation Finland, and published in the Leukemia series.

(PRESS RELEASE) HELSINKI, 6-Nov-2023 — /EuropaWire/ — A study by the University of Helsinki, HUS Helsinki University Hospital and Aalto University investigated why some blood cancer patients can discontinue their medication safely. The study advances the effective treatment of patients.

Chronic myeloid leukaemia (CML), one of the four main types of blood cancer, affects the blood-forming cells in the bone marrow. Each year, some 50 Finns are diagnosed with CML, mostly in people of working age.

Because the onset mechanism of the disease has been accurately identified, targeted drugs (tyrosine kinase inhibitors) now ensure that only a few patients die of disease.

Researchers aim to develop the treatment of CML so that patients can discontinue their medication after a certain period. In such cases, the cancer may be considered cured.

In a recent study, Finnish researchers investigated why some patients with CML can discontinue their daily medication safely.

The researchers compared such patients with others. Attempts at medication discontinuation succeeded more often if the patient had a favourable immune system.

“Even before attempting to discontinue treatment, the successful patients had more natural killer cells, or NK cells, and T cells able to detect cancer. We also explored the mechanisms of these cells for detecting tumours and found new medication potential,” explains Jani Huuhtanen, a doctoral researcher and doctor specialising in haematology at the University of Helsinki, Aalto University and the HUS Comprehensive Cancer Center.

Immune system can be boosted

The results can be used to develop new treatment solutions for medication discontinuation. In fact, the research group already has experience in such trials.

“Last year, we published an article on our trial involving not only targeted treatment but also interferon-alpha treatment activating the body’s immune system. Patients achieved better responses with this combination therapy, which could enable a drug free life for more patients,” says Huuhtanen.

“Based on these and our previous results, we believe the body’s own immune response to cancer cells must first be triggered to allow more patients to stop taking their medication,” notes Satu Mustjoki of the University of Helsinki, who heads the Translational Immunology Research Program.

At present, some 40% of all CML patients have an excellent response to treatment and can thus discontinue their medication.

Next, the researchers aim to further examine the mechanisms of drug discontinuation and find out whether the body’s immune system can be boosted in other cancer types as well.

The Finnish study was published in the Leukemia series.

The study was funded by the European Research Council (ERC), the Research Council of Finland, the Cancer Foundation Finland, the Sigrid Jusélius Foundation and the Signe and Ane Gyllenberg Foundation, and carried out under the iCAN Digital Precision Cancer Medicine Flagship funded by the Research Council of Finland.
Original article: Huuhtanen, J., Adnan-Awad, S., Theodoropoulos, J., Forstén, S., Warfvinge, R., Dufva, O., Bouhlal, J., Dhapola, P., Duàn, H., Laajala, E., Kasanen, T., Klievink, J., Ilander, M., Jaatinen, T., Olsson-Strömberg, U., Hjorth-Hansen, H., Burchert, A., Karlsson, G., Kreutzman, A., Lähdesmäki, H., Mustjoki, S. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia, 2023. DOI: 10.1038/s41375-023-02074-w

Media Contact:

Jani Huuhtanen
Doctoral Researcher
TRANSLATIONAL IMMUNOLOGY RESEARCH PROGRAM
jani.huuhtanen@helsinki.fi

Satu Mustjoki
Professor
DEPARTMENT OF CLINICAL CHEMISTRY AND HEMATOLOGY
satu.mustjoki@helsinki.fi

SOURCE: University of Helsinki